Procaps Group, S.A.
PROCW
NASDAQ Global Market0.02
USD
+0.00
- -
CIK
0001863362
ISIN
LU2376491259
CUSIP
L7756P110
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-92.21
76.60
5Y
-98.20
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jose Antonio Toledo Vieira
- Full Time Employees
- 5,500
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 9 rue de Bitbourg Luxembourg City Luxembourg 1273
- IPO Date
- Sep 30, 2021
- CIK
- 0001863362
- Website
- procapsgroup.com
- Similar Companies
- Business
- Procaps Group, S.A. is a multinational pharmaceutical and healthcare company specializing in the development, manufacture, and marketing of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The company offers a diverse portfolio of products including over-the-counter (OTC) pharmaceutical products, prescription pharmaceutical drugs (Rx), nutritional supplements, and high-potency clinical solutions. Its operations span pharmaceutical brands across Latin America and extend to services in contract development and manufacturing (CDMO) with a focus on advanced softgel technologies. Procaps serves more than 50 countries on five continents, with direct presence in 13 countries in the Americas. Founded in 1977 and headquartered in Luxembourg, Procaps Group operates through multiple business segments including NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics, catering to markets in the United States, Brazil, Colombia, Central America, and the Andean region. The company also provides diabetes solutions and chronic disease management tools through its Diabetrics segment. Its vertically integrated facilities enable end-to-end solutions across the pharmaceutical value chain, supported by a workforce of nearly 5,000 employees. Recent major company developments include a $130 million equity investment and comprehensive debt restructuring completed in 2025, led by new strategic investors including Hoche Partners Pharma Holdings. Procaps also secured a $40 million secured convertible note and restructured its board of directors, introducing new leadership focusing on turnaround strategies, operational optimization, and financial oversight. The company continues to focus on improving operational efficiencies, optimizing cash flow, and returning to growth trajectory following financial challenges highlighted in ongoing investigations and financial restatements. In 2022, Procaps expanded its geographic footprint and manufacturing capacity through the acquisition of Grupo Somar, a significant pharmaceutical group in Mexico, enhancing its product portfolio and R&D capabilities. This acquisition represents a strategic step in broadening its presence in the Latin American pharmaceutical market and advancing its roll-up strategy for regional consolidation. The company also added a U.S.-based softgel manufacturing facility and pharmaceutical R&D center to boost global growth in its iCDMO (integrated Contract Development and Manufacturing Organization) business segment. Procaps Group’s product offerings encompass exclusive prescription brand medicines, complex hospital-use medications, OTC and generic health products for family use, nutritional supplements, and advanced softgel capsules. The company emphasizes innovation, quality management, and compliance with international regulatory standards, maintaining a robust pipeline with over 500 formulations and an average of 50 new product launches annually.